<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00301990</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000460074</org_study_id>
    <secondary_id>UCLA-050658-01</secondary_id>
    <secondary_id>DMS-W0454</secondary_id>
    <nct_id>NCT00301990</nct_id>
    <nct_alias>NCT00142142</nct_alias>
  </id_info>
  <brief_title>Bevacizumab and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer</brief_title>
  <official_title>A Phase II Study of Bevacizumab and Aldesleukin in Patients With Metastatic Renal Cell Carcinoma (RCC): A Cytokine Working Group (CWG) Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jonsson Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different&#xD;
      ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and&#xD;
      help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the&#xD;
      growth of tumor cells by blocking blood flow to the tumor. Interleukin-2 may stimulate the&#xD;
      white blood cells to kill tumor cells. Giving bevacizumab together with interleukin-2 may&#xD;
      kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well giving bevacizumab together with&#xD;
      interleukin-2 works in treating patients with metastatic kidney cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Estimate the response, progression-free survival, and overall survival of patients with&#xD;
           metastatic renal cell carcinoma (RCC) treated with bevacizumab and high-dose&#xD;
           interleukin-2 (IL-2).&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Compare the response and survival of patients with metastatic RCC treated with&#xD;
           bevacizumab and high-dose IL-2 with the historical data of patients treated with&#xD;
           high-dose IL-2 alone.&#xD;
&#xD;
        -  Compare the toxicity of bevacizumab and high-dose IL-2 in patients with metastatic RCC&#xD;
           with the historical data of patients treated with high-dose IL-2 alone, in terms of&#xD;
           number of doses of IL-2 administered during the first course of therapy, toxicity after&#xD;
           the scheduled ninth dose of IL-2, and frequency of grade III and IV or unexpected or&#xD;
           rare toxicities.&#xD;
&#xD;
        -  Compare the time to disease progression in patients with metastatic RCC treated with&#xD;
           bevacizumab and high-dose IL-2 with the historical data of patients treated with&#xD;
           high-dose IL-2 alone.&#xD;
&#xD;
        -  Evaluate the pharmacokinetics and pharmacodynamics of bevacizumab and high-dose IL-2&#xD;
           during course 1.&#xD;
&#xD;
        -  Correlate serum vascular endothelial growth factor (VEGF) levels, DC function, TCR zeta&#xD;
           chain expression, and arginase or arginine levels with toxicity, response, and survival&#xD;
           of patients treated with this regimen.&#xD;
&#xD;
        -  Evaluate the utility of known prognostic criteria for RCC patients on clinical outcome.&#xD;
&#xD;
      OUTLINE: This is a multicenter study. Patients are stratified according to prognosis (good vs&#xD;
      intermediate vs poor).&#xD;
&#xD;
      Patients receive bevacizumab IV over 30-90 minutes on days -13, 1, 15, 29, 43, 57, and 71&#xD;
      during course 1 and on days 1, 15, 29, 43, 57, and 71 during courses 2 and 3. Patients also&#xD;
      receive high-dose interleukin-2 every 8 hours on days 1-5 and 15-19. Treatment repeats every&#xD;
      84 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed every 3 months for 2 years and&#xD;
      then every 6 months thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 65 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2005</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression-free and overall survival</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of response and survival with historical data</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to disease progression</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics and pharmacodynamics</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of serum VEGF levels, DC function, TCR zeta chain expression, and arginase or arginine levels with toxicity, response, and survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Utility of known prognostic criteria</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">65</enrollment>
  <condition>Kidney Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>aldesleukin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>bevacizumab</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed metastatic renal cell carcinoma (RCC) with predominantly&#xD;
             clear cell histology&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
          -  No history of tumor-related hemorrhage&#xD;
&#xD;
          -  No history of CNS or brain metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Karnofsky performance status ≥ 80%&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,000/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin ≥ 9 g/dL (transfusion or recombinant erythropoietin growth factors allowed)&#xD;
&#xD;
          -  AST ≤ 2 times upper limit of normal (ULN) (5 times ULN if due to liver metastases)&#xD;
&#xD;
          -  Serum total bilirubin ≤ 2 times ULN (except for patients with Gilbert's disease)&#xD;
&#xD;
          -  Serum creatinine ≤ 1.5 mg/dL OR creatinine clearance ≥ 60 mL/min&#xD;
&#xD;
          -  FEV_1 ≥ 2.0 L or ≥ 75% of predicted&#xD;
&#xD;
               -  Pulmonary function testing required for patients over age 50 or with significant&#xD;
                  pulmonary or smoking history&#xD;
&#xD;
          -  No history of cerebrovascular accident or transient ischemic attacks&#xD;
&#xD;
          -  No evidence of any of the following cardiac conditions*:&#xD;
&#xD;
               -  Congestive heart failure&#xD;
&#xD;
               -  Symptoms of coronary artery disease&#xD;
&#xD;
               -  Myocardial infarction &lt; 6 months prior to study entry&#xD;
&#xD;
               -  Serious cardiac arrhythmias&#xD;
&#xD;
               -  Unstable angina NOTE: *Patients &gt; 40 years old or who have had a previous&#xD;
                  myocardial infarction &gt; 6 months prior to study entry are required to have a&#xD;
                  negative or low probability cardiac stress test for cardiac ischemia&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No other malignancy within the past 5 years except nonmelanoma skin cancer or&#xD;
             noninvasive cancer, such as cervical carcinoma in situ, superficial bladder cancer&#xD;
             without local recurrence, or breast cancer in situ&#xD;
&#xD;
               -  Patients with a history of another invasive malignancy must be in complete&#xD;
                  remission for ≥ 5 years&#xD;
&#xD;
          -  No positive serology for HIV, hepatitis B, or hepatitis C&#xD;
&#xD;
          -  No significant co-morbid illness, such as uncontrolled diabetes or active infection,&#xD;
             that would preclude study treatment&#xD;
&#xD;
          -  No history of inflammatory bowel disease or other serious autoimmune disease&#xD;
&#xD;
               -  Thyroiditis or rheumatoid arthritis allowed&#xD;
&#xD;
          -  No uncontrolled hypertension (i.e., blood pressure &gt; 150/100 mm Hg)&#xD;
&#xD;
          -  Proteinuria ≤ 3+ by dipstick OR proteinuria &lt; 2 gm by 24-hour urine collection&#xD;
&#xD;
          -  Urine protein:creatinine ration &lt; 1.0&#xD;
&#xD;
          -  No abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within&#xD;
             6 months prior to study entry&#xD;
&#xD;
          -  No significant traumatic injury within the past 28 days&#xD;
&#xD;
          -  No serious, nonhealing wound, ulcer, or bone fracture&#xD;
&#xD;
          -  No active bleeding&#xD;
&#xD;
          -  No history of other serious hemorrhage, bleeding diathesis, or underlying coagulopathy&#xD;
&#xD;
          -  No history of deep venous thrombosis, clinically significant peripheral vascular&#xD;
             disease, or other thrombotic event&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  No organ allografts&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy or surgery and recovered&#xD;
&#xD;
          -  No prior systemic therapy for metastatic RCC&#xD;
&#xD;
          -  No prior bevacizumab or interleukin-2&#xD;
&#xD;
          -  At least 2 weeks since prior steroids&#xD;
&#xD;
          -  No major surgery or open biopsy within the past 28 days&#xD;
&#xD;
          -  No minor surgical procedures, fine needle aspirations, or core biopsies within the&#xD;
             past 7 days, except central venous catheter placement&#xD;
&#xD;
          -  No concurrent major surgery&#xD;
&#xD;
          -  No concurrent corticosteroids or other immunosuppressants&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fairooz F. Kabbinavar, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Jonsson Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jonsson Comprehensive Cancer Center at UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-1781</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Jonsson Comprehensive Cancer Center a</last_name>
      <phone>888-798-0719</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cardinal Bernardin Cancer Center at Loyola University Medical Center</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Cardinal Bernardin Cancer Center</last_name>
      <phone>708-226-4357</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Indiana University Melvin and Bren Simon Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202-5289</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Indiana University Cancer Center</last_name>
      <phone>317-274-2552</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Beth Israel Deaconess Medical Center</last_name>
      <phone>617-667-9925</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Barbara Ann Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201-1379</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Barbara Ann Karmanos Cancer Institute</last_name>
      <phone>313-576-9363</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756-0002</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Norris Cotton Cancer Center</last_name>
      <phone>603-650-7609</phone>
      <email>cancerhelp@dartmouth.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Our Lady of Mercy Medical Center Comprehensive Cancer Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10466</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janice P. Dutcher, MD</last_name>
      <phone>718-304-7200</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Providence Cancer Center at Providence Portland Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213-2967</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Providence Cancer Center at Providenc</last_name>
      <phone>503-215-6412</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>UPMC Cancer Centers</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - UPMC Cancer Centers</last_name>
      <phone>412-647-8073</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vanderbilt-Ingram Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232-6838</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Vanderbilt-Ingram Cancer Center</last_name>
      <phone>800-811-8480</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Virginia Cancer Center</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Geoffrey R. Weiss, MD</last_name>
      <phone>434-243-0066</phone>
      <email>grw3k@virginia.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2007</verification_date>
  <study_first_submitted>March 10, 2006</study_first_submitted>
  <study_first_submitted_qc>March 10, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 13, 2006</study_first_posted>
  <last_update_submitted>January 9, 2014</last_update_submitted>
  <last_update_submitted_qc>January 9, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 10, 2014</last_update_posted>
  <keyword>stage IV renal cell cancer</keyword>
  <keyword>recurrent renal cell cancer</keyword>
  <keyword>clear cell renal cell carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aldesleukin</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

